Online Only Articles

Spleen tyrosine kinase inhibitors reduce CD40L-induced proliferation of chronic lymphocytic leukemia cells but not normal B cells

Centre for Immune Regulation, Institute of Clinical Medicine, University of Oslo, Norway
Centre for Molecular Medicine Norway, Nordic EMBL Partnership, University of Oslo and Oslo University Hospital, Norway;Biotechnology Centre, K. G. Jebsen Centre for Inflammation Research and K. G. Jebsen Centre for Cancer Immunotherapy, University of Oslo, Norway
Centre for Immune Regulation, Institute of Clinical Medicine, University of Oslo, Norway;Department for Haematology, Oslo University Hospital, Rikshospitalet, Oslo & Institute of Clinical Medicine, University of Oslo, Norway
Centre for Immune Regulation, Institute of Clinical Medicine, University of Oslo, Norway
Centre for Immune Regulation, Institute of Clinical Medicine, University of Oslo, Norway
Centre for Immune Regulation, Institute of Clinical Medicine, University of Oslo, Norway;KG Jebsen Centre for Influenza Vaccine Research, Institute of Clinical Medicine, University of Oslo, Norway
Department for Haematology, Oslo University Hospital, Rikshospitalet, Oslo & Institute of Clinical Medicine, University of Oslo, Norway
Centre for Molecular Medicine Norway, Nordic EMBL Partnership, University of Oslo and Oslo University Hospital, Norway;Biotechnology Centre, K. G. Jebsen Centre for Inflammation Research and K. G. Jebsen Centre for Cancer Immunotherapy, University of Oslo, Norway;Department of Infectious Diseases, Oslo University Hospital, Norway
Centre for Immune Regulation, Institute of Clinical Medicine, University of Oslo, Norway
Vol. 101 No. 2 (2016): February, 2016 https://doi.org/10.3324/haematol.2015.135590